OakChart

Beam Therapeutics Inc

BEAMHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 11:27 AM ET

25.45+0.30 (1.19%)
2026-11-11 17:27 CET
Market cap
2,602.92 USD m
Revenue, TTM
146.64 USD m
Net income, TTM
-107.10 USD m
Free cash flow, TTM
-398.24 USD m
EPS diluted, TTM
-1.04
P/E
-
Compare

Price

BEAM against its 20, 50 and 200-day averages
2050200miss
25.0030.0035.003.1M6.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BEAMclose 25.4520-day 25.7150-day 25.38200-day 27.9225.4552w high

33.5% under the 52-week high of 38.26 on 7 Jul 2026. 52-week low 20.23 on 20 Nov 2025. Last 15 sessions, 28.1% high to low

Profile

BEAM
52-week range, 29% of the way up
20.2338.26

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

IndexRUT
Employees511
IPOFeb 06, 2020
Beta2.23
ATR, 14d1.71
Rel volume0.90
Short float27.33%
Insider own7.81%
Inst own100.97%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.63B
Enterprise Value1.83B
Income-107.10M
Sales146.64M
Book/sh9.21
Cash/sh10.09
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees511
IPOFeb 06, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S17.96
P/B2.76
P/C2.52
P/FCF-
EV/EBITDA-
EV/Sales12.51
Quick Ratio13.00
Current Ratio13.00
Debt/Eq0.26
LT Debt/Eq0.24
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.04
EPS next Y-5.20
EPS next Q-1.25
EPS this Y-470.07%
EPS next Y-12.63%
EPS next 5Y-
EPS past 3/5Y41.92% 28.04%
Sales past 3/5Y31.88% 466.27%
EPS Y/Y TTM77.49%
Sales Y/Y TTM163.27%
EPS Q/Q-16.81%
Sales Q/Q-96.83%
EarningsNov 03 BMO
EPS/Sales Surpr.-10.85% -96.49%

Ownership

Insider Own7.81%
Insider Trans-4.74%
Inst Own100.97%
Inst Trans0.54%
ROA-8.30%
ROE-11.16%
ROIC-9.07%
Gross Margin84.91%
Oper. Margin-267.68%
Profit Margin-73.04%
SMA20-1.01%
SMA500.29%
SMA200-8.86%
Trades-

Technical

Shs Outstand103.44M
Shs Float95.42M
Short Float27.33%
Short Ratio13.88
Short Interest26.08M
52W High38.26 -33.48%
52W Low20.23 25.80%
Volatility8.13% 6.52%
ATR (14)1.71
RSI (14)48.52
Beta2.23
Rel Volume0.90
Avg Volume1.88M
Volume568,068

Performance

Perf Week-8.42%
Perf Month4.18%
Perf Quarter-4.00%
Perf Half Y-20.09%
Perf YTD-8.19%
Perf Year13.21%
Perf 3Y14.85%
Perf 5Y-72.75%
Perf 10Y-
Recom1.25
Target Price48.93
Prev Close25.15
Price25.45
Change %1.19%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Feb 20, 2026InitiatedCCanaccord GenuityBuy$74+190.8%
Oct 09, 2025InitiatedJJefferiesBuy$41+61.1%
Mar 28, 2025UpgradeBBofA SecuritiesNeutral → Buy$42+65.0%
Mar 10, 2025UpgradeBScotiabankSector Perform → Sector Outperform$40+57.2%
Jan 29, 2025UpgradeCCantor FitzgeraldNeutral → Overweight
Nov 06, 2024UpgradeLLeerink PartnersMarket Perform → Outperform$27 → $39+53.2%
Oct 16, 2024InitiatedBScotiabankSector Outperform
Jul 23, 2024InitiatedHH.C. WainwrightBuy$80+214.3%
Jan 29, 2024UpgradeJJP MorganNeutral → Overweight$38 → $40+57.2%
Dec 15, 2023DowngradeBBofA SecuritiesBuy → Neutral$35+37.5%

Peers

Mkt cap
TickerCompanyMkt cap
NTLAIntellia Therapeutics Inc1.62B
CRSPCRISPR Therapeutics AG4.43B
PRMEPrime Medicine Inc781.73M
EDITEditas Medicine Inc383.53M
WVEWave Life Sciences Inc675.51M
SCTXScribe Therapeutics Inc335.65M
KRROKorro Bio Inc207.87M
ARWRArrowhead Pharmaceuticals Inc6.92B
VRTXVertex Pharmaceuticals Inc137.17B
DTILPrecision Biosciences Inc255.89M

Insider trading

latest 14 of 52
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Evans John M.CEOOct 15 '26Option Exercise1.0325,00025,7501,072,205Oct 16 08:09 PM
Evans John M.CEOOct 16 '26Option Exercise1.0325,00025,7501,072,205Oct 16 08:09 PM
Evans John M.CEOOct 16 '26Sale23.9825,000599,5951,047,205Oct 16 08:09 PM
Evans John M.CEOOct 15 '26Sale23.5725,000589,1501,047,205Oct 16 08:09 PM
JOHN M EVANSOfficerOct 16 '26Proposed Sale23.9825,000599,595Oct 16 04:12 PM
JOHN M EVANSOfficerOct 15 '26Proposed Sale23.5725,000589,150Oct 15 04:23 PM
Cavanagh Bethany JSVP, Finance and TreasurerOct 01 '26Sale24.411874,56550,984Oct 02 04:05 PM
Simon AmyChief Medical OfficerJul 27 '26Sale25.7416,667429,03785,696Jul 29 04:05 PM
AMY SIMONOfficerJul 27 '26Proposed Sale25.7416,677429,294Jul 27 04:04 PM
Simon AmyChief Medical OfficerJun 30 '26Sale34.7337312,954102,363Jul 02 04:05 PM
Evans John M.CEOJun 30 '26Option Exercise1.0325,00025,7501,072,205Jul 01 04:05 PM
Evans John M.CEOJun 29 '26Option Exercise0.7625,00019,0311,072,205Jul 01 04:05 PM
Evans John M.CEOJun 29 '26Sale35.4925,000887,3521,047,205Jul 01 04:05 PM
Evans John M.CEOJun 30 '26Sale34.3125,000857,6851,047,205Jul 01 04:05 PM

Held by

AUM
TickerCompanyAUM
ARKEARK DIET Q3 Buffer ETFAUM: 1.45M
ARKKARK Innovation ETFAUM: 5.97B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
ARKGARK Genomic Revolution ETFAUM: 1.97B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B

News

latest 14 of 206
  • Beams base editing therapy for sickle cell hits goal in pivotal trial (BioPharma Dive) -6.92%
  • Beam Therapeutics to seek approval of SCD cell therapy after trial success (Clinical Trials Arena)
  • Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease (GlobeNewswire)
  • Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +5.55%
  • Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio (GlobeNewswire)
  • Loading…
  • Cathie Wood Loads Up On TEM, ILMN And Biotech Stocks But Pares Stake In This Pharma Giant That Had A Blowout Q3 (Stocktwits)
  • BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside (Stocktwits)
  • Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress (GlobeNewswire)
  • Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress (GlobeNewswire)
  • Beam sues 2 biotechs, alleging theft of base editing trade secrets (BioPharma Dive)
  • Cathie Wood Makes $64 Million Bet on Two Stocks (GuruFocus.com)
  • Anthropic AI Discovery Gene-Editing Stocks Falling (GuruFocus.com)
  • Beyond Meta, Cathie Woods ARKG Loads Up On These 4 Biotech Names (Stocktwits)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-1.280-1.155-1.2800.318.7515
2026Q22026-08-04-1.180-1.106-1.1760.4916.3713
2026Q12026-05-07-0.910-1.028-0.91331.7410.9816
2025Q42026-02-242.330-1.0102.328114.1111.6716
2025Q32025-11-04-1.100-1.038-1.0999.7011.3414
2025Q22025-08-05-1.000-1.113-1.0038.4712.7715
2025Q12025-05-06-1.240-1.184-1.2427.4714.0215
2024Q42025-02-25-1.090-1.228-1.09130.0717.1716
2024Q32024-11-05-1.170-1.183-1.17314.2714.5217
2024Q22024-08-06-1.110-1.127-1.10611.7714.1814
2024Q12024-05-07-1.210-1.415-1.2087.4117.0912
2023Q42024-02-271.730-0.6911.727316.1918.6714
2023Q32023-11-08-1.220-1.329-1.21617.1917.0913
2023Q22023-08-08-1.080-1.425-1.08420.1217.3213
2023Q12023-05-10-1.330-1.320-1.33524.2115.6112
2022Q42023-02-28-0.540-1.357-0.54220.0413.2115

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-13.687--1.7730.01-
2020FY-4.190-2.917-4.1910.020.01
2021FY-5.770-5.702-5.77151.8411.60
2022FY-4.130-4.733-4.12960.9254.19
2023FY-1.720-4.250-1.718377.7179.64
2024FY-4.580-4.685-4.57763.5251.41
2025FY-0.810-4.220-0.810139.7435.99
2026FY--4.618--38.49
2027FY--5.201--28.23
2028FY--4.947--62.53
2029FY--3.759--237.58
2030FY--1.812--591.98

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0915235.660.0016.00
2026Q4S2026-11-0515235.660.0016.00
2026Q4S2026-11-0415235.660.0016.00
2026Q4S2026-11-0315217.680.0032.22
2026Q4S2026-10-20141010.130.0032.22
2026Q4S2026-10-19141110.130.0032.22
2026Q4S2026-10-18142210.130.0032.22
2026Q4S2026-10-16142310.130.0032.22
2026Q4S2026-09-04142410.130.0032.22
2026Q4S2026-08-06141510.100.0032.22
2026Q4S2026-08-05141411.990.0032.22
2026Q4S2026-08-04140312.680.0031.74
2026Q4S2026-07-22120017.280.0036.70
2026Q4S2026-07-21121017.280.0036.70

Estimate history

EPS, annual-0.195-2.289-1.773-4.191-5.771-4.129-1.718-4.577-0.809-1.0448
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.173-1.091-1.242-1.003-1.0992.328-0.913-1.176-1.284
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000.0180.02451.84460.92377.70963.518139.743146.64
Period201720182019202020212022202320242025TTM
Sales, quarterly14.26930.0677.478.4669.698114.10931.7380.490.307
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual49.71251.25151.3457.25468.38971.27781.63283.633101.749103.443
Period201720182019202020212022202320242025MRQ
Shares, quarterly82.55983.633100.557100.759101.36101.749102.742103.265103.443
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue146.64139.7463.52377.7160.9251.840.020.020.00
Cost of Goods Sold Incl. D&A22.1322.2921.9320.0122.5816.449.475.410.65
Gross Profit124.52117.4541.59357.7038.3435.40-9.45-5.39-0.65
Selling, General and Administrative Excl. Other517.05501.14457.16534.18376.82427.87123.3169.7745.09
Research and Development409.00409.62367.56437.38311.59387.09103.1854.6233.87
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-392.54-383.69-415.57-176.49-338.48-392.46-132.76-75.15-45.74
Interest Expense-----0.01-0.190.00
Unusual Expense4.26-4.8210.231.35-63.00-21.8463.405.4016.07
Net Income Before Taxes-107.10-79.99-376.70-131.16-260.18-370.64-194.59-78.33-116.74
Income Taxes0.000.000.041.373.410.000.000.000.00
Consolidated Net Income-107.10-79.99-376.74-132.53-289.09-370.64-194.59-78.33-116.74
Net Income From Continuing Operations-107.10-79.99-376.74-132.53-289.09-370.64-194.59-78.33-115.26
Net Income-107.10-79.99-376.74-132.53-289.09-370.64-195.87-91.04-117.33
EPS (Recurring)-0.99-0.84-4.49-1.71-4.76-6.01-3.24-1.70-2.07
EPS (Basic, Before Extraordinaries)-1.00-0.81-4.58-1.72-4.13-5.77-4.19-1.77-2.29
EPS (Diluted)-1.04-0.81-4.58-1.72-4.13-5.77-4.19-1.77-2.29
EBITDA-370.41-361.40-393.64-156.47-315.90-376.02-123.29-69.75-45.09
Non-Operating Income (Expense)289.69298.8849.0946.6815.300.001.572.42-54.92
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense69.0374.4595.3277.9366.6143.5715.387.037.00
Price To Sales Ratio17.4619.6232.145.5644.9598.73158,970.84--
Gross Margin84.9184.0565.4894.7062.9468.29-39,366.67-29,938.89-
Operating Margin-267.68-274.57-654.25-46.73-555.61-757.01-553,166.67-417,522.22-
Net Margin-73.04-57.24-593.13-35.09-474.54-714.91-816,120.83-505,777.78-
Shares Outstanding103.44101.7583.6381.6371.2868.3957.2551.3451.25
Market Capitalization2,602.922,602.922,053.582,218.542,756.045,429.744,634.224,684.17-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.310.4931.74114.119.708.477.4730.07
Cost of Goods Sold Incl. D&A5.455.415.615.675.565.545.535.44
Gross Profit-5.14-4.9226.13108.444.142.931.9424.62
Selling, General and Administrative Excl. Other136.18121.63133.35125.89130.95123.08121.23124.66
Research and Development110.1195.10104.5299.28109.77101.7698.82101.44
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-141.32-126.55-107.22-17.45-126.81-120.15-119.29-100.04
Unusual Expense-0.824.07-3.034.04-3.18-5.53-0.151.25
Net Income Before Taxes-134.41-122.68-94.32244.30-112.73-102.29-109.27-90.35
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-134.41-122.68-94.32244.30-112.73-102.29-109.27-90.35
Net Income From Continuing Operations-134.41-122.68-94.32244.30-112.73-102.29-109.27-90.35
Net Income-134.41-122.68-94.32244.30-112.73-102.29-109.27-90.35
EPS (Recurring)-1.29-1.15-0.932.36-1.12-1.04-1.24-1.08
EPS (Basic, Before Extraordinaries)-1.28-1.18-0.912.37-1.10-1.00-1.24-1.09
EPS (Diluted)-1.28-1.18-0.912.33-1.10-1.00-1.24-1.09
EBITDA-135.88-121.14-101.61-11.78-121.25-114.61-113.76-94.59
Non-Operating Income (Expense)6.097.949.87265.7910.9012.339.8610.93
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense18.5519.2815.0416.1517.9724.3726.6823.87
Price To Sales Ratio17.4622.9515.0020.8144.6928.7927.0232.34
Gross Margin-1,673.62-1,004.0882.3495.0342.6734.5926.0081.90
Operating Margin-46,033.22-25,827.14-337.81-15.29-1,307.60-1,419.22-1,596.87-332.71
Net Margin-43,780.13-25,036.33-297.18214.09-1,162.38-1,208.26-1,462.78-300.51
Shares Outstanding103.44103.26102.74101.75101.36100.76100.5683.63
Market Capitalization2,602.923,530.812,427.232,812.892,455.201,710.471,949.882,053.58

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments1,245.21850.741,189.881,078.13965.65299.6791.85146.441.90
Short Term Receivables0.000.000.000.00300.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets23.4827.4121.1714.767.368.652.701.830.14
Total Current Assets1,268.69878.151,211.041,092.901,273.01308.3294.54148.282.04
Net Property, Plant & Equipment205.18216.28237.81234.13186.98125.3743.2516.940.34
Total Investments and Advances6.688.148.7212.7512.7514.8413.331.490.03
Intangible Assets--------0.00
Other Assets0.631.252.151.931.723.144.980.300.00
Total Assets1,481.181,103.821,459.711,341.711,474.45451.68156.10167.012.40
Short Term Debt Incl. Current Port. of LT Debt14.3613.4713.2612.239.836.345.640.001.01
Accounts Payable10.233.871.629.037.476.317.857.350.73
Other Current Liabilities72.34164.73190.69202.33196.1389.6915.6518.244.83
Total Current Liabilities96.94182.07205.56223.59213.44102.3429.1425.596.57
Long Term Debt139.76147.96159.91169.78137.82101.3125.600.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities6.1240.26112.91214.87296.462.470.427.400.02
Total Liabilities242.82370.28478.38608.24647.72206.1255.1532.986.58
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00302.05251.435.26
Common Equity1,238.36733.54981.33733.47826.74245.56-201.10-117.41-9.44
Total Shareholders Equity1,238.36733.54981.33733.47826.74245.56100.94134.03-4.18
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,238.36733.54981.33733.47826.74245.56100.94134.03-4.18
Total Liabilities & Stockholders Equity1,481.181,103.821,459.711,341.711,474.45451.68156.10167.012.40
Book Value Per Share12.178.7712.0210.2912.094.29-3.92-2.29-0.19
Tangible Book Value Per Share12.178.7712.0210.2912.094.29-3.92-2.29-0.19
Full-Time Employees5114834365073411811188787
Price to Book Ratio2.732.592.773.866.5919.0320.80--
Return on Assets-6.19-29.39-9.46-20.53-38.49-64.03-48.48-136.07-
Return on Equity-8.11-43.94-15.46-37.06-69.13-112.32-66.67-177.53-
Return on Invested Capital-5.80-42.74-11.61-32.01-38.43-56.10-61.90-85.99-
Quick Ratio13.094.825.894.895.963.013.245.790.31
Current Ratio13.094.825.894.895.963.013.245.790.31

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-107.10-79.99-376.74-132.53-289.09-370.64-194.59-78.33-116.74
Depreciation22.1322.2921.9320.0122.5816.449.475.410.65
Other Funds (Non Cash)-175.03-156.39117.7979.7837.41176.6884.0311.6285.72
Funds from Operations-260.01-214.09-237.02-32.74-229.10-177.52-101.09-61.30-30.37
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-128.64-131.02-110.22-116.45251.63111.255.35-10.7110.07
Cash from Operating Activities-388.65-345.10-347.25-149.1922.53-66.27-95.74-72.00-20.30
Capital Expenditures-9.59-14.95-8.95-33.73-48.95-46.81-16.36-12.52-13.12
Net Assets From Acquisitions0.00-0.080.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.620.000.000.00
Purchase or Sale of Investments235.25-106.41193.95105.57-412.38-247.95-83.77-54.14-0.30
Purchase of Investments-805.38-1,209.79-486.44-984.34-1,617.00-777.22-282.36-130.21-0.30
Sale Or Maturity of Investments1,040.631,103.38680.391,089.911,204.61529.27198.6076.07-
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities225.66-121.44185.0171.84-461.34-294.14-100.12-66.66-13.42
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock15.27478.058.22278.70113.88758.26320.6235.56179.73
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock15.27478.058.22278.70113.88758.26320.6235.56179.73
Proceedsfrom Stock Options2.88473.282.62272.57111.14748.63317.4735.38179.72
Issuance or Reduction of Debt, Net93.070.00-0.48-2.25-2.29-2.121.705.710.00
Change in Long Term Debt93.070.00-0.48-2.25-2.29-2.121.705.710.00
Issuance of Long Term Debt93.070.000.000.000.000.003.276.180.00
Reduction of Long Term Debt0.000.00-0.48-2.25-2.29-2.12-1.57-0.460.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities108.34478.057.74276.45111.59756.14322.3241.28179.73
Net Change in Cash-54.6411.51-154.50199.09-327.22395.73126.46-97.38146.00
Free Cash Flow-398.24-360.05-356.19-182.93-26.42-113.08-112.10-84.52-33.42
Preferred Dividends (Cash Flow)-0.000.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments1,043.871,152.931,211.651,245.211,074.971,150.34
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets23.5025.6755.3023.4823.5825.13
Total Current Assets1,067.381,178.601,266.951,268.691,098.551,175.46
Net Property, Plant & Equipment187.03193.19199.40205.18205.28208.39
Total Investments and Advances6.716.716.696.686.666.63
Other Assets7.967.867.760.630.590.67
Total Assets1,269.071,386.361,480.801,481.181,311.081,391.16
Short Term Debt Incl. Current Port. of LT Debt15.6415.2114.7814.3612.6912.95
Accounts Payable20.1413.1012.2910.239.5410.56
Other Current Liabilities46.2952.5847.5072.34160.33150.63
Total Current Liabilities82.0880.8874.5696.94182.56174.13
Long Term Debt228.23232.15236.04139.76138.73141.85
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities6.095.885.756.1223.7928.36
Total Liabilities316.40318.91316.36242.82345.08344.34
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity952.671,067.441,164.441,238.36966.001,046.81
Total Shareholders Equity952.671,067.441,164.441,238.36966.001,046.81
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity952.671,067.441,164.441,238.36966.001,046.81
Total Liabilities & Stockholders Equity1,269.071,386.361,480.801,481.181,311.081,391.16
Book Value Per Share9.2110.3411.3312.179.5310.39
Tangible Book Value Per Share9.2110.3411.3312.179.5310.39
Full-Time Employees---511--
Price to Book Ratio2.733.031.962.912.341.52
Return on Assets-8.30-6.15-4.41-6.19-33.41-30.05
Return on Equity-11.16-8.08-5.69-8.11-47.19-41.94
Return on Invested Capital-11.38-9.44-6.7317.73-10.20-8.61
Quick Ratio13.0014.5716.9913.096.026.75
Current Ratio13.0014.5716.9913.096.026.75

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-134.41-122.68-94.32244.30-112.73-102.29
Depreciation5.455.415.615.675.565.54
Other Funds (Non Cash)17.5922.9515.82-231.3932.8116.86
Funds from Operations-111.37-94.31-72.8918.57-74.36-79.89
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.6228.22-55.62-101.86-7.123.44
Cash from Operating Activities-110.75-66.10-128.51-83.29-81.48-76.45
Capital Expenditures-1.21-2.41-2.23-3.73-5.01-3.14
Net Assets From Acquisitions0.000.000.000.00-0.080.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments103.07-7.4627.50112.1470.74-167.28
Purchase of Investments-109.63-180.92-153.79-361.04-175.64-333.94
Sale Or Maturity of Investments212.70173.46181.29473.18246.39166.67
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities101.86-9.8825.27108.4165.66-170.41
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.337.523.541.891.681.11
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.337.523.541.891.681.11
Proceedsfrom Stock Options1.370.001.510.001.26-0.65
Issuance or Reduction of Debt, Net0.000.0093.070.000.000.00
Change in Long Term Debt0.000.0093.070.000.000.00
Issuance of Long Term Debt0.000.0093.070.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.337.5296.611.891.681.11
Net Change in Cash-6.56-68.45-6.6427.00-14.15-245.75
Free Cash Flow-111.96-68.51-130.75-87.02-86.49-79.59

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 63.52M 2025: 139.74M
United States2024: 63.52M 2025: 139.74M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3027.33%26.1M95.4M1.83M
2026-10-1527.56%26.2M95.2M1.87M
2026-09-3028.93%27.5M95.2M1.99M
2026-09-1527.55%25.9M94.0M2.14M
2026-08-3127.47%25.8M93.9M2.13M
2026-08-1425.95%24.4M93.9M2.15M
2026-07-3125.12%23.5M93.6M2.25M
2026-07-1524.91%23.2M93.2M2.27M
2026-06-3024.41%22.9M93.7M2.18M
2026-06-1530.19%28.3M93.8M2.10M
2026-05-2922.88%21.5M93.8M2.10M
2026-05-1528.28%26.5M93.8M2.10M
2026-04-3022.35%20.9M93.7M2.00M
2026-04-1523.96%22.2M92.7M1.95M
2026-03-3125.15%23.4M92.9M2.00M
2026-03-1322.94%21.3M92.9M1.83M
2026-02-2723.57%21.9M92.9M1.78M
2026-02-1321.78%20.2M92.9M1.84M
2026-01-3021.21%19.4M91.5M2.00M
2026-01-1521.90%20.0M91.5M2.11M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.008.0012.9011.205.27767.000.000.909-0.1130.007
call16.007.0011.900.004.8000.000.000.900-0.1110.007
call17.006.0010.900.004.3970.000.000.889-0.1070.008
call18.005.009.306.003.4592.000.000.877-0.1040.008
call19.004.008.305.143.1702.000.000.862-0.0990.009
call20.003.107.906.903.30663.000.000.845-0.0950.010
call21.002.506.503.632.6593.000.000.824-0.0890.010
call22.001.155.904.232.39121.000.000.795-0.0820.011
call23.000.704.901.602.3803020.000.748-0.0770.013
call24.000.353.901.492.0293160.000.662-0.0920.015
call25.000.152.451.241.4103800.000.574-0.1040.016
call26.000.201.450.801.0603981.000.526-0.1580.016
call27.000.500.950.570.9891410.000.419-0.1100.016
call28.000.051.200.251.1646100.000.340-0.0960.015
call29.000.101.600.151.3561760.000.306-0.1060.014
call30.000.050.650.361.2854841.000.237-0.0880.012
call31.000.004.900.141.4215080.000.221-0.0940.012
call32.000.004.900.101.5841160.000.206-0.0990.011
call33.000.004.500.251.6666.000.000.197-0.1030.011
call34.000.004.900.081.79059.000.000.188-0.1070.011
call35.000.000.350.351.49677.000.000.111-0.0600.008
call36.000.000.300.121.60433.000.000.108-0.0660.007
call37.000.004.900.101.74526.000.000.102-0.0680.007
call38.000.003.200.051.7897.000.000.099-0.0690.007
call39.000.004.902.401.9114.000.000.095-0.0710.007
call40.000.001.000.631.9511320.000.093-0.0720.007
call41.000.004.300.102.02681.000.000.090-0.0730.007
call42.000.004.902.012.13816.000.000.088-0.0740.006
call43.000.004.901.152.2095.000.000.085-0.0750.006
call44.000.004.900.102.2771.000.000.084-0.0760.006
call45.000.000.100.052.24745.000.000.082-0.0720.006
call50.000.004.901.152.1759040.000.033-0.0350.003
call55.000.004.900.052.4113.000.000.031-0.0360.003
put15.000.004.900.103.04112.000.00-0.093-0.1110.007
put16.000.004.900.202.7834.000.00-0.101-0.1080.007
put17.000.004.100.752.5093.000.00-0.112-0.1050.008
put18.000.004.900.232.1935.000.00-0.128-0.1000.008
put19.000.004.900.251.9398.000.00-0.143-0.0950.009
put20.000.002.500.201.72830.000.00-0.158-0.0910.010
put21.000.004.900.411.69032.000.00-0.208-0.1050.011
put22.000.001.000.371.28859.000.00-0.203-0.0800.011
put23.000.150.650.801.0547150.00-0.242-0.0730.013
put24.000.450.750.750.88692.002.00-0.332-0.0890.015
put25.000.751.401.301.0371341.00-0.420-0.1010.016
put26.000.004.901.672.90468.000.00-0.471-0.1570.016
put27.000.304.901.852.51410.000.00-0.572-0.1100.016
put28.000.804.902.752.1063170.00-0.660-0.0930.015
put29.002.006.003.802.36753.000.00-0.693-0.1020.014
put30.003.007.004.202.54884.000.00-0.761-0.0850.012
put31.004.007.904.892.6524.000.00-0.778-0.0900.012
put32.004.008.809.302.7675.000.00-0.793-0.0960.011
put33.005.1010.008.402.9887.000.00-0.804-0.1000.011
put34.006.1011.008.503.1268.000.00-0.813-0.1030.011
put35.007.1012.006.653.2492.000.00-0.876-0.0680.008
put36.008.1013.000.003.4170.000.00-0.892-0.0620.007
put37.009.1014.0012.303.5016.000.00-0.897-0.0640.007
put38.0010.1015.007.703.6052.000.00-0.901-0.0650.007
put39.0011.1016.000.003.7230.000.00-0.904-0.0660.007
put40.0012.1017.007.603.8270.000.00-0.907-0.0680.007
put41.0013.1018.000.003.9320.000.00-0.910-0.0690.007
put42.0014.1019.000.004.0230.000.00-0.912-0.0700.006
put43.0015.1020.000.004.1160.000.00-0.914-0.0710.006
put44.0016.1021.000.004.2050.000.00-0.916-0.0720.006
put45.0017.1022.000.004.2920.000.00-0.963-0.0290.003
put50.0022.1027.000.004.6570.000.00-0.967-0.0300.003
put55.0027.1032.000.005.0150.000.00-0.969-0.0300.003

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-10-16144Filing for proposed sale of securities under Rule 144.SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-10-15SEC
2026-10-15144Filing for proposed sale of securities under Rule 144.SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-27144Filing for proposed sale of securities under Rule 144.SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-294Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-088-KCurrent report2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-04-29SCHEDULE 13GSEC
2026-04-17ARSAnnual report to security holders. 2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.19M3
2026-090000
2026-080000
2026-0700429.04K1
2026-060011.80M5
2026-050000
2026-04001.42M5
2026-03001.13M2
2026-02001.12M1
2026-01002.44M6
2025-1200204.55K2
2025-110000

Institutional holders

Manager% owned
FMR LLC12.51%
FARALLON CAPITAL MANAGEMENT, L.L.C.9.95%
ARK Investment Management LLC9.95%
BlackRock, Inc.8.75%
STATE STREET CORP5.66%
VANGUARD PORTFOLIO MANAGEMENT LLC4.78%
VANGUARD CAPITAL MANAGEMENT LLC4.47%
ARCH Venture Management, LLC4.41%
Amova Asset Management Americas, Inc.3.36%
PRICE T ROWE ASSOCIATES INC /MD/3.32%

Funds

Fund% owned
ARK Innovation ETF5.91%
Fidelity Growth Company Fund3.35%
State Street(R) SPDR(R) S&P(R) Biotech ETF3.28%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
iShares Russell 2000 ETF2.47%
VANGUARD SMALL-CAP INDEX FUND2.30%
ARK Genomic Revolution ETF2.24%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.32%
VANGUARD EXTENDED MARKET INDEX FUND1.11%
Fidelity Small Cap Index Fund1.05%

OakChart. BEAM. Cached 15 minutes.